JP5580043B2 - 放射線増感増強剤 - Google Patents

放射線増感増強剤 Download PDF

Info

Publication number
JP5580043B2
JP5580043B2 JP2009512893A JP2009512893A JP5580043B2 JP 5580043 B2 JP5580043 B2 JP 5580043B2 JP 2009512893 A JP2009512893 A JP 2009512893A JP 2009512893 A JP2009512893 A JP 2009512893A JP 5580043 B2 JP5580043 B2 JP 5580043B2
Authority
JP
Japan
Prior art keywords
cells
gene
promoter
tumor
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009512893A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2008136213A1 (ja
Inventor
俊義 藤原
紀章 田中
俊哉 藤原
泰生 浦田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolys Biopharma Inc
Original Assignee
Oncolys Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolys Biopharma Inc filed Critical Oncolys Biopharma Inc
Priority to JP2009512893A priority Critical patent/JP5580043B2/ja
Publication of JPWO2008136213A1 publication Critical patent/JPWO2008136213A1/ja
Application granted granted Critical
Publication of JP5580043B2 publication Critical patent/JP5580043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10041Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009512893A 2007-04-27 2008-03-06 放射線増感増強剤 Active JP5580043B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009512893A JP5580043B2 (ja) 2007-04-27 2008-03-06 放射線増感増強剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007119858 2007-04-27
JP2007119858 2007-04-27
PCT/JP2008/054564 WO2008136213A1 (fr) 2007-04-27 2008-03-06 Agent amplifiant la radiosensibilité
JP2009512893A JP5580043B2 (ja) 2007-04-27 2008-03-06 放射線増感増強剤

Publications (2)

Publication Number Publication Date
JPWO2008136213A1 JPWO2008136213A1 (ja) 2010-07-29
JP5580043B2 true JP5580043B2 (ja) 2014-08-27

Family

ID=39943332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512893A Active JP5580043B2 (ja) 2007-04-27 2008-03-06 放射線増感増強剤

Country Status (2)

Country Link
JP (1) JP5580043B2 (fr)
WO (1) WO2008136213A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110628703A (zh) * 2019-10-30 2019-12-31 复旦大学附属金山医院 一种放射性肺损伤体外细胞模型及其构建方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510435A (ja) * 1994-09-06 2000-08-15 ラ ホヤ キャンサー リサーチ ファウンデーション アデノウイルスe1aを用いて腫瘍細胞を感作する方法
JP2003504052A (ja) * 1999-07-12 2003-02-04 セント ルイス ユニヴァーシティ 複製−コンピテント抗癌ベクター
JP2003511032A (ja) * 1999-10-04 2003-03-25 エーバーハルト−カルルス−ウニヴェルズィテート テュービンゲン ウニヴェルズィテートクリーニクム 遺伝子治療用の腫瘍特異的ベクター
WO2003025190A1 (fr) * 2001-09-14 2003-03-27 The New Industry Research Organization Agent promoteur de tumeur specifique et utilisation associee
JP2004033186A (ja) * 2002-07-08 2004-02-05 Kansai Tlo Kk 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
WO2005052143A2 (fr) * 2003-11-14 2005-06-09 Per Sonne Holm Adenovirus, acides nucleiques les codant et utilisations associees
JP2006500956A (ja) * 2002-10-01 2006-01-12 デューク・ユニバーシティ 腫瘍の低酸素領域で選択的に複製する組み換えアデノウイルスベクターの使用による、標的腫瘍治療

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510435A (ja) * 1994-09-06 2000-08-15 ラ ホヤ キャンサー リサーチ ファウンデーション アデノウイルスe1aを用いて腫瘍細胞を感作する方法
JP2003504052A (ja) * 1999-07-12 2003-02-04 セント ルイス ユニヴァーシティ 複製−コンピテント抗癌ベクター
JP2003511032A (ja) * 1999-10-04 2003-03-25 エーバーハルト−カルルス−ウニヴェルズィテート テュービンゲン ウニヴェルズィテートクリーニクム 遺伝子治療用の腫瘍特異的ベクター
WO2003025190A1 (fr) * 2001-09-14 2003-03-27 The New Industry Research Organization Agent promoteur de tumeur specifique et utilisation associee
JP2004033186A (ja) * 2002-07-08 2004-02-05 Kansai Tlo Kk 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
JP2006500956A (ja) * 2002-10-01 2006-01-12 デューク・ユニバーシティ 腫瘍の低酸素領域で選択的に複製する組み換えアデノウイルスベクターの使用による、標的腫瘍治療
WO2005052143A2 (fr) * 2003-11-14 2005-06-09 Per Sonne Holm Adenovirus, acides nucleiques les codant et utilisations associees

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6008025980; KISHIMOTO,H. et al: 'In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus' Nat Med Vol.12, No.10, 2006, p.1213-1219 *
JPN6008025983; FUJIWARA,T. et al: 'Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxe' Int J Cancer Vol.119, No.2, 2006, p.432-440 *
JPN6008025986; MARTIN-DUQUE,P. et al: 'In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors' Int J Oncol Vol.15, No.6, 1999, p.1163-1168 *
JPN6008025988; SANCHEZ-PRIETO, R. et al: 'The adenovirus E1a gene: Therapeutic activity in tumor pathology.' Oncologia Vol.20, No.11, 1997, 33-43 *

Also Published As

Publication number Publication date
WO2008136213A1 (fr) 2008-11-13
JPWO2008136213A1 (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
JP6639412B2 (ja) アルブミン結合部分を含んでなるアデノウイルス
US20240100106A1 (en) Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
KR101294238B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
Zhu et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo
Franco-Luzón et al. Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma
EP2746388A2 (fr) Adénovirus recombiné comprenant un ribozyme présentant une activité de trans-épissage et un gène destiné à traiter le cancer, et son utilisation
EP1553178B1 (fr) Virus oncolytique se propageant de manière sélective dans les cellules tumorales
JP2018518986A (ja) 腫瘍溶解性hsv1ベクターおよび使用法
US7491525B2 (en) Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it
Faghihkhorasani et al. The role of oncolytic virotherapy and viral oncogenes in the cancer stem cells: a review of virus in cancer stem cells
KR20230057336A (ko) 메티오니나아제의 유전자 요법의 악성 종양에의 응용
JP5580043B2 (ja) 放射線増感増強剤
Kanaya et al. Anti-tumor effect of adenoviral vector-mediated p53 gene transfer on the growth of canine osteosarcoma xenografts in nude mice
Zhang et al. Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
WO2011118819A1 (fr) Thérapie génique pour une tumeur du tissue hématopoïétique par vecteur viral à prolifération régulée portant un promoteur de la survivine
WO2020166727A1 (fr) Virus oncolytique utilisant l'adénovirus humain de type 35 comme base
KR102471898B1 (ko) 면역관문 억제제를 발현하는 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
JP7406263B2 (ja) 改変アデノウイルス及びこれを含む医薬
NL2031110B1 (en) Recombinant adeno-associated virus vector, recombinant adeno-associated virus aav8-pd1 and use thereof
US20240165175A1 (en) Muc16 promoter containing virus
US20220154218A1 (en) Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
CN113186172A (zh) 共表达Apoptin与MEL基因的重组腺病毒及构建方法和应用
AU2022210147A9 (en) Cancer-specific trans-splicing ribozyme expressing immune checkpoint inhibitor, and use thereor
Jung et al. Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells
Oosterhoff et al. 594. Gene-directed enzyme therapy with carboxylesterase/CPT-11, but not thymidine kinase/GCV, enhances the efficacy of the conditionally replicating adenovirus Ad [Delta] 24

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131112

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20140129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140410

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140710

R150 Certificate of patent or registration of utility model

Ref document number: 5580043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250